Fatty liver/NAFLD, type 2 diabetes (T2DM).
Conditions
Interventions
High fat meal with 13C labeled fatty acids
Sponsors
Maastricht University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria: Lean subjects (study 1): - Age 18-65 years - Normal BMI 18-25 kg/m2 - Stable dietary habits - Generally healthy, no medication use Obese subjects (study 2): - Age 18-65 years, - Obese, BMI 30-35 kg/m2 - Stable dietary habits (no weight-reducing diet last year) - Generally healthy, no medication use
Exclusion criteria
Exclusion criteria: Persons that have any of the following will be excluded from the study: - Any medical condition requiring treatment and/or medication use - Alcohol consumption of more than 20 g per day (± 2 units) or other drug abuse - Unstable body weight (weight gain or loss > 3 kg in the past three months) - Contraindications for MRI scan: • Aneurysm clips • Implanted neural stimulator • Implanted cardiac pacemaker of defibrillator • Cochlear implant • Iron- containing corpora aliena in the eye or brain • Artificial (heart) valves which is contraindicated for MRS • Claustrophobia - Subjects, who do not want to be informed about unexpected medical findings, or do not wish that their treating physician is informed, cannot participate in the study. Possible unexpected findings could include: dark or highlighted spots in the liver or contrast differences between different muscle groups. In case one of those unexpected findings are recognised by the performing researcher, a radiologist will be contacted first for advice. On his/her advice further investigations will be performed and/or the physician will be contacted.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters per study-group are: Studie 1 (lean subjects) -Determination of the lowest dose that allows for sufficient signal to noise ratio and to determine time of maximal 13C accumulation in liver. Time point of maximal increase. Studie 2 (obese subjects) -Minimal dose for significant postprandial increase of enrichment in liver. -Time point of maximal increase. -Difference in dose compared to lean subjects. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Total- and 13C-enriched blood plasma levels of FFA, triglycerides, glucose. | — |
Contacts
Public ContactLucas Lindeboom
Outcome results
None listed